Shots:
With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturing
While major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…
Shots:
Biopharma companies have kept themselves afloat in the ocean of uncertainties by overcoming the hurdles of unmet demands, procurement, and maintaining a constant supply chain. However, the previous year was difficult for biopharma companies as the segment saw multiple insolvencies.
Amidst all kinds of obstacles, many companies have sustained themselves to meet the market…
Shots:
Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions
Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years. Some companies accept the offered period and open doors to biological drugs or biosimilars. In…
Shots:
The EMA approved 7 New Chemical Entity (NCE) and 5 Biologic Drugs in February 2023, leading to treatments for patients and advances in the healthcare industry
In February 2023, the major highlights drugs were Forxiga’s Approval for symptomatic chronic heart failure, Fintepla for adjunctive treatment of seizures associated with lennox-gastaut syndrome
PharmaShots has compiled…
Shots:
Post M&A deals, companies often cannot sail through a few key aspects of the partnership, such as limited ownership, exorbitant recovery costs, and poor integration process, leading to deal terminations. The improperly executed expansion program also contributes significantly to the failed partnership
To tackle such scenarios, companies are cautious enough to make backup plans beforehand…
Active Ingredient: Ibrutinib
Dosage Forms & Strengths:
Capsules: 70 mg and 140 mg
Tablets: 140 mg, 280 mg, 420 mg, and 560 mg
Mechanism of Action: Bruton's tyrosine kinase Inhibitor (BTKi)
First Approval: US (13 Nov 2013), EU (Oct 2014)
Revenue Analysis
Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one…
Shots:
The 41st Annual J.P. Morgan Healthcare Conference took place on 09 – 12 January 2023 in San Francisco, CA, USA. It is the largest and most informative healthcare investment symposium in the industry, bringing together a cohort of industry leaders, emerging fast-growing companies, innovative technology creators, and members of the investment community
The major announcement…
Shots:
Mergers and Acquisitions are among the predominant elements of the Biopharma Industry. Owing to the repercussions of the Russia-Ukraine war and the ongoing COVID-19 pandemic, the IPOs, public markets, anti-trust law reforms by the US FTC, and M&As among others were relatively low in the biopharma sector in the year 2022
In the year…
The year 2022 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements, clinical trial results and gaining approvals. Our team has compiled a list of 30 most read life sciences news on PharmaShots in 2022
1. AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to…
Shots:
The EMA approved 4 New Chemical Entity (NCE) and 4 Biologic Drugs in November 2022, leading to treatments for patients and advances in the healthcare industry
In November 2022, the major highlights drugs were Skyrizi's approval for active crohn's disease, Beyfortus for RSV lower respiratory tract disease
PharmaShots has compiled a list of a…

